<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820885</url>
  </required_header>
  <id_info>
    <org_study_id>CL0600-022</org_study_id>
    <nct_id>NCT00820885</nct_id>
  </id_info>
  <brief_title>A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide</brief_title>
  <official_title>A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to study the safety and tolerability of teduglutide&#xD;
      following a once or possibly twice daily subcutaneous injection for eight consecutive days in&#xD;
      healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide&#xD;
      following a once or possibly twice daily injection for eight consecutive days in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects are enrolled once they have been screened and it is determined they qualify.&#xD;
      The subjects are randomized to either placebo or the dose of teduglutide as outlined by the&#xD;
      protocol at a 1:3 ratio. They will be injected with investigational product for eight&#xD;
      consecutive days, with measurements taken including safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2006</start_date>
  <completion_date type="Actual">April 23, 2007</completion_date>
  <primary_completion_date type="Actual">April 23, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Each dose arm is safe</measure>
    <time_frame>Within 1 week of each cohort completion</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Pharmacokinetics and Safety of Elevated Doses</condition>
  <arm_group>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 mg dose 20 mg/ML concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 mg in 50 mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>15 mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>80mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide</intervention_name>
    <description>subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.</description>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_label>cohort I</arm_group_label>
    <other_name>Gattex is the brand name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide</intervention_name>
    <description>Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water</description>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_label>cohort I</arm_group_label>
    <other_name>Gattex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tedguglutide</intervention_name>
    <description>lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.</description>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_label>cohort I</arm_group_label>
    <other_name>Gattex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women between 20 and 55 years of age&#xD;
&#xD;
          -  BMI of 18-35 inclusive&#xD;
&#xD;
          -  Able to understand and sign informed consent form&#xD;
&#xD;
          -  Willing and able to be confined at the clinical research center 8.5 days&#xD;
&#xD;
          -  Women who are post-menopausal, surgically sterilized, or agree to use effective form&#xD;
             of birth control&#xD;
&#xD;
          -  Women of child bearing potential with a negative pregnancy test at screening and&#xD;
             check-in&#xD;
&#xD;
          -  Medically healthy with normal clinical results and ECG/lab profiles at screening and&#xD;
             check-in&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Donated 1 pint or more of blood/blood products within 56 days prior to study or&#xD;
             received plasma within 7 days prior to study&#xD;
&#xD;
          -  Pregnancy or become pregnant&#xD;
&#xD;
          -  Participated in another investigational trial 30 days prior&#xD;
&#xD;
          -  Physical examination/medical history indicates clinical condition or concurrent&#xD;
             illness unsuitable for study&#xD;
&#xD;
          -  History/presence of clincally significant disease of any body system&#xD;
&#xD;
          -  History/evidence of congenital hon-hemolytic hyperbilirubinemia&#xD;
&#xD;
          -  History/evidence of gall stone disease, stomach or intestinal surgery&#xD;
&#xD;
          -  History/evidence of colorectal cancer&#xD;
&#xD;
          -  History/evidence of GI disease, e.g., malabsorption, Crohn's Disease, etc.&#xD;
&#xD;
          -  History/evidence of skin rashes or dermatitis&#xD;
&#xD;
          -  Taking prescription or over the counter medication (with the exception of oral&#xD;
             contraception) during the 7 days preceding confinement to the clinical unit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

